CA2320958A1 - Immunisation par bibliotheque d'antigenes - Google Patents

Immunisation par bibliotheque d'antigenes Download PDF

Info

Publication number
CA2320958A1
CA2320958A1 CA 2320958 CA2320958A CA2320958A1 CA 2320958 A1 CA2320958 A1 CA 2320958A1 CA 2320958 CA2320958 CA 2320958 CA 2320958 A CA2320958 A CA 2320958A CA 2320958 A1 CA2320958 A1 CA 2320958A1
Authority
CA
Canada
Prior art keywords
polypeptide
antigens
antigen
recombinant
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2320958
Other languages
English (en)
Inventor
Juha Punnonen
Steven H. Bass
Robert Gerald Whalen
Russell Howard
Willem P.C. Stemmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320958A1 publication Critical patent/CA2320958A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une immunisation par bibliothèque d'antigènes mettant en oeuvre des méthodes qui produisent des antigènes présentant des propriétés améliorées et destinés à un usage thérapeutiques ou autres. Ces méthodes permettent d'obtenir des antigènes améliorés pouvant produire une réponse immunitaire contre des agents pathogènes, le cancer ou d'autres affections, ainsi que des antigènes pouvant moduler efficacement des maladies allergiques, inflammatoires ou auto-immunes.
CA 2320958 1998-02-11 1999-02-10 Immunisation par bibliotheque d'antigenes Abandoned CA2320958A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7429498P 1998-02-11 1998-02-11
US2176998A 1998-02-11 1998-02-11
US60/074,294 1998-02-11
US09/021,769 1998-02-11
US10550998P 1998-10-23 1998-10-23
US60/105,509 1998-10-23
PCT/US1999/002944 WO1999041383A1 (fr) 1998-02-11 1999-02-10 Immunisation par bibliotheque d'antigenes

Publications (1)

Publication Number Publication Date
CA2320958A1 true CA2320958A1 (fr) 1999-08-19

Family

ID=27361726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2320958 Abandoned CA2320958A1 (fr) 1998-02-11 1999-02-10 Immunisation par bibliotheque d'antigenes

Country Status (5)

Country Link
EP (1) EP1054973A1 (fr)
JP (1) JP2002507393A (fr)
AU (1) AU3289199A (fr)
CA (1) CA2320958A1 (fr)
WO (1) WO1999041383A1 (fr)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
WO1999023107A1 (fr) 1997-10-31 1999-05-14 Maxygen, Incorporated Modification du tropisme viral et de la diversite d'especes hote par recombinaison du genome viral
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
WO1999065927A2 (fr) 1998-06-17 1999-12-23 Maxygen, Inc. Technique de production de polynucleotides aux caracteristiques souhaitees
WO2000009682A1 (fr) 1998-08-12 2000-02-24 Maxygen, Inc. Rearrangement d'adn de genes de monoxygenase en vue de la production de produits chimiques industriels
CA2345203A1 (fr) 1998-10-07 2000-04-13 Maxygen Inc. Rearrangement d'adn pour produire des acides nucleiques de detoxication contre les mycotoxines
EP1129184A1 (fr) 1998-11-10 2001-09-05 Maxygen, Inc. Adp-glucose pyrophosphorylase modifiee pour l'amelioration et l'optimisation de phenotypes vegetaux
AUPP706098A0 (en) * 1998-11-11 1998-12-03 North Western Health Care Network Biological compositions, components thereof and uses therefor
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1130093A1 (fr) 1999-01-19 2001-09-05 Maxygen, Inc. Recombinaison d'acides nucléiques moyennant des oligonucléotides
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
JP2003524394A (ja) 1999-02-11 2003-08-19 マキシジェン， インコーポレイテッド ハイスループット質量分析法
US6531316B1 (en) 1999-03-05 2003-03-11 Maxyag, Inc. Encryption of traits using split gene sequences and engineered genetic elements
AU7288600A (en) * 1999-09-21 2001-04-24 Artemis Pharmaceuticals Gmbh Method for identifying mhc-restricted antigens
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
GB9928787D0 (en) * 1999-12-03 2000-02-02 Medical Res Council Direct screening method
WO2001044828A1 (fr) * 1999-12-17 2001-06-21 Maxygen, Inc. Procedes de detection parallele de compositions ayant des caracteristiques desirees par spectroscopie irm
IL150291A0 (en) 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
WO2001059071A2 (fr) 2000-02-09 2001-08-16 Genvec, Inc. Methodes de preparation et d'utilisation d'une bibliotheque de vecteurs viraux
CA2411828A1 (fr) 2000-06-23 2002-01-03 Maxygen, Inc. Nouvelles molecules costimulatrices
AU2001268716A1 (en) 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US7367155B2 (en) 2000-12-20 2008-05-06 Monsanto Technology Llc Apparatus and methods for analyzing and improving agricultural products
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
EP2322185A3 (fr) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Thérapie à base de polynucléotides
EP1572941A4 (fr) 2002-02-26 2009-03-18 Maxygen Inc Nouveaux antigenes de flavivirus
EP1493027B1 (fr) 2002-03-01 2014-10-15 Codexis Mayflower Holdings, LLC Procedes, systemes et logiciel pour identifier des biomolecules fonctionnelles
US7620500B2 (en) 2002-03-09 2009-11-17 Maxygen, Inc. Optimization of crossover points for directed evolution
PT1499545E (pt) 2002-04-04 2008-03-20 Monsanto Technology Llc Sistema automatizado de triagem, pesagem e recolha de matéria particulada
US20030236396A1 (en) * 2002-04-09 2003-12-25 Nicholas Fasel Secretory signal sequences and uses thereof
AU2003243157C1 (en) 2002-04-19 2008-09-04 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2005003289A2 (fr) 2002-08-06 2005-01-13 Verdia, Inc. Variants de l'amine oxydase ap1
DK2194133T3 (en) 2003-03-06 2016-02-29 Basf Enzymes Llc Amylases, nucleic acids encoding them, and methods of making and using the same
EP2853593B1 (fr) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
US7592434B2 (en) 2003-04-04 2009-09-22 Verenium Corporation Pectate lyases, nucleic encoding them and methods for making and using them
CN1863914B (zh) 2003-04-29 2011-03-09 先锋高级育种国际公司 新的草甘膦-n-乙酰转移酶(gat)基因
CN103484486B (zh) 2003-07-02 2018-04-24 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
EP1668113B1 (fr) 2003-08-11 2013-06-19 Verenium Corporation Laccases, acides nucleiques codant pour ces enzymes et procedes permettant de les produire et de les utiliser
BRPI0414708B1 (pt) 2003-09-23 2019-05-14 Monsanto Technology Llc Sistema e método para processamento de sementes.
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
AU2005254993B2 (en) 2004-06-09 2009-08-06 Pioneer Hi-Bred International, Inc. Plastid transit peptides
CN101432292B (zh) 2004-06-16 2013-03-13 维莱尼姆公司 对叶绿素进行酶促脱色的组合物和方法
AR050469A1 (es) 2004-08-26 2006-10-25 Monsanto Technology Llc Ensayo automatico de semillas
US7703238B2 (en) 2004-08-26 2010-04-27 Monsanto Technology Llc Methods of seed breeding using high throughput nondestructive seed sampling
EP2886658A1 (fr) 2005-03-10 2015-06-24 BASF Enzymes LLC Enzymes de lyase, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
MX300732B (es) 2005-03-15 2012-06-28 Verenium Corp Celulasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
US8715988B2 (en) 2005-03-28 2014-05-06 California Institute Of Technology Alkane oxidation by modified hydroxylases
WO2006125983A1 (fr) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions permettant d'induire une reponse immunitaire contre l'hepatite b
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
WO2007094852A2 (fr) 2006-02-10 2007-08-23 Verenium Corporation Enzymes cellulolytiques, acides nucléiques codant pour elles et procédés pour les préparer et les utiliser
EP2548955A1 (fr) 2006-02-14 2013-01-23 Verenium Corporation Xylanases, acides nucléiques les codant et leurs procédés de fabrication et dýutilisation
US8028469B2 (en) 2006-03-02 2011-10-04 Monsanto Technology Llc Automated high-throughput seed sampler and methods of sampling, testing and bulking seeds
US7998669B2 (en) 2006-03-02 2011-08-16 Monsanto Technology Llc Automated contamination-free seed sampler and methods of sampling, testing and bulking seeds
EP1996937A4 (fr) * 2006-03-06 2009-04-08 Amunix Inc Materiels génétiques et utilisations correspondantes
CA2644548A1 (fr) * 2006-03-06 2007-09-13 Amunix, Inc. Materiels genetiques et utilisations correspondantes
BRPI0708614A2 (pt) 2006-03-07 2011-06-07 Verenium Corp aldolases, ácidos nucléicos codificando as mesmas e métodos para produzir e usar as mesmas
MX2008011477A (es) 2006-03-07 2008-09-23 Cargill Inc Aldolasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
BRPI0713106B1 (pt) 2006-06-28 2018-10-16 Monsanto Technology Llc sistema e método para selecionar pequenos objetos
BRPI0714876B1 (pt) 2006-08-04 2022-04-19 Verenium Corporation Ácido nucleico isolado, sintético ou recombinante, cassete de expressão, vetor ou veículo de clonagem, célula bacteriana, fúngica ou de levedura transformada, polipeptídeo isolado, sintético ou recombinante, composição, bem como métodos de produção e de usos dos mesmos
AR062947A1 (es) 2006-09-21 2008-12-17 Verenium Corp Fosfolipasas acidos nucleicos que las codifican y metodos para prepararlas y usarlas
JP5307013B2 (ja) 2006-09-21 2013-10-02 ヴェレニウム コーポレイション フィターゼ、フィターゼをコードする核酸、並びにフィターゼを製造および使用する方法
PL2069490T5 (pl) 2006-12-21 2018-09-28 Basf Enzymes Llc Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich
NZ578309A (en) 2007-01-30 2012-06-29 Verenium Corp Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
US8189901B2 (en) 2007-05-31 2012-05-29 Monsanto Technology Llc Seed sorter
EP2000531A1 (fr) * 2007-06-06 2008-12-10 Biomay AG Cellules présentant l'antigène
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2009045627A2 (fr) 2007-10-03 2009-04-09 Verenium Corporation Xylanases, acides nucléiques codant pour elles et leurs méthodes d'obtention et d'utilisation
DK2238261T3 (da) 2008-01-03 2014-02-10 Verenium Corp Isomeraser, nukleinsyrer der koder for dem og fremgangsmåder til fremstilling og anvendelse deraf
CA2710683A1 (fr) 2008-01-03 2009-07-16 Verenium Corporation Transferases et oxydoreductases, acides nucleiques codant pour celles-ci, et leurs procedes de fabrication et d'utilisation
WO2009143397A2 (fr) 2008-05-23 2009-11-26 E. I. Du Pont De Nemours And Company Nouveaux gènes dgat permettant d'obtenir une production accrue de lipides de stockage de semences et des profils modifiés d'acides gras dans des plantes à graines oléagineuses
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
CA2738472A1 (fr) 2008-09-26 2010-04-22 Tocagen Inc. Vecteurs de therapie genique et cytosines deaminases
CA2748314C (fr) 2009-02-03 2018-10-02 Amunix Operating Inc. Polypeptides recombinants etendus et compositions les comprenant
WO2010135588A2 (fr) 2009-05-21 2010-11-25 Verenium Corporation Phytases, acides nucléiques codant pour elles et procédés de fabrication et d'utilisation associés
IN2012DN01359A (fr) 2009-08-20 2015-06-05 Pioneer Hi Bred Int
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
US20110191903A1 (en) 2009-12-31 2011-08-04 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
CN103237894A (zh) 2010-08-13 2013-08-07 先锋国际良种公司 包含具有羟基苯丙酮酸双加氧酶(hppd)活性的序列的组合物和方法
CA2864126A1 (fr) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Proteines de facteur viii de recombinaison
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
BR112014027468A2 (pt) 2012-05-04 2017-06-27 Du Pont polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo.
BR112015023286A2 (pt) 2013-03-14 2018-03-06 Arzeda Corp polipeptídeo recombinante com atividade da dicamba descarboxilase, construto de polinucleotídeo, célula, método de produção de uma célula hospedeira compreendendo um polinucleotídeo heterólogo que codifica um polipeptídeo tendo atividade da dicamba descarboxilase, método para descarboxilar dicamba, um derivado de dicamba ou um metabolito de dicamba, método para a detecção de um polipeptideo e método para a detecção da presença de um polinucleotideo que codifica um polipeptideo tendo atividade da dicamba descarboxilase
AU2014236154A1 (en) 2013-03-14 2015-09-17 Pioneer Hi-Bred International, Inc. Compositions having dicamba decarboxylase activity and methods of use
US9353158B2 (en) 2013-03-14 2016-05-31 Altravax, Inc. Hepatitis B virus vaccines
CA2901316A1 (fr) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Polypeptides phi-4 et leurs procedes d'utilisation
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
MX359026B (es) 2013-08-16 2018-09-12 Pioneer Hi Bred Int Proteinas insecticidas y metodos de uso.
CA3223359A1 (fr) 2013-09-13 2015-03-19 Pioneer Hi-Bred International, Inc. Proteines insecticides et leurs procedes d'utilisation
WO2015120270A1 (fr) 2014-02-07 2015-08-13 Pioneer Hi Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
CA3290904A1 (en) 2014-02-07 2026-03-02 E. I. Du Pont De Nemours And Company Insecticidal proteins and methods for their use
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
JP6824154B2 (ja) 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
KR102532832B1 (ko) 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
CA2963558C (fr) 2014-10-16 2023-04-04 Pioneer Hi-Bred International, Inc. Proteines insecticides et leurs procedes d'utilisation
CN107635396B (zh) 2015-01-15 2021-12-24 先锋国际良种公司 杀昆虫蛋白及其使用方法
CN107529763B (zh) 2015-03-11 2021-08-20 先锋国际良种公司 Pip-72的杀昆虫组合及使用方法
ES2938072T3 (es) * 2015-05-11 2023-04-04 Illumina Inc Plataforma para el descubrimiento y análisis de agentes terapéuticos
CN116333064A (zh) 2015-05-19 2023-06-27 先锋国际良种公司 杀昆虫蛋白及其使用方法
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US10925950B2 (en) 2015-08-03 2021-02-23 University Of Washington Immunogenic compositions, antigen screening methods, and methods of generating immune responses
CA3268091A1 (en) 2015-08-06 2026-03-02 Pioneer Hi-Bred International, Inc. Plant derived insecticidal proteins and methods for their use
WO2017105987A1 (fr) 2015-12-18 2017-06-22 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
MX387077B (es) 2016-05-04 2025-03-19 Pioneer Hi Bred Int Proteinas insecticidas y metodos para sus usos.
CA3026113A1 (fr) 2016-07-01 2018-01-04 Pioneer Hi-Bred International, Inc. Proteines insecticides issues de plantes et procedes pour leur utilisation
MX387927B (es) 2016-11-01 2025-03-19 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
EP3555118B1 (fr) 2016-12-14 2021-08-18 Pioneer Hi-Bred International Inc. Protéines insecticides et leurs procédés d'utilisation
WO2018118811A1 (fr) 2016-12-22 2018-06-28 Pioneer Hi-Bred International, Inc. Protéines insecticides et leurs procédés d'utilisation
MX2019009371A (es) 2017-02-08 2019-09-23 Pionner Hi Bred Int Inc Combinaciones insecticidas de proteinas insecticidas derivadas de plantas y metodos para su uso.
MX2019013321A (es) 2017-05-11 2020-02-10 Pioneer Hi Bred Int Proteinas insecticidas y metodos para su uso.
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
AU2019234566B2 (en) 2018-03-14 2024-09-26 Hexima Limited Insecticidal proteins from plants and methods for their use
CN111867377B (zh) 2018-03-14 2023-05-23 先锋国际良种公司 来自植物的杀昆虫蛋白及其使用方法
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
JP2022521217A (ja) * 2019-02-19 2022-04-06 メディカゴ インコーポレイテッド ロタウイルスｖｐ７融合タンパク質およびそれらを含むロタウイルス様粒子
MX2022008463A (es) 2020-01-10 2022-10-18 Univ California Plataforma biosintética para la producción de ácido olivetólico y análogos del ácido olivetólico.
US12280102B2 (en) 2020-04-17 2025-04-22 Vlp Therapeutics, Inc. Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
JP2023524055A (ja) 2020-04-30 2023-06-08 ブイエルピー・セラピューティクス・インコーポレイテッド サイトカイン免疫療法
BR112022025113A2 (pt) 2020-06-30 2022-12-27 Monsanto Technology Llc Sistemas automatizados para uso em separação de pequenos objetos, e métodos relacionados
US12168774B2 (en) 2020-07-14 2024-12-17 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691170A (en) * 1989-04-18 1997-11-25 Therion Biologics Generation of hybrid genes and proteins by virus-mediated recombination
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination

Also Published As

Publication number Publication date
EP1054973A1 (fr) 2000-11-29
AU3289199A (en) 1999-08-30
JP2002507393A (ja) 2002-03-12
WO1999041383A1 (fr) 1999-08-19
WO1999041383A8 (fr) 1999-09-30

Similar Documents

Publication Publication Date Title
US6576757B1 (en) Polynucleotides encoding flavivirus and alphavirus multivalent antigenic polypeptides
CA2320958A1 (fr) Immunisation par bibliotheque d'antigenes
CN1909922B (zh) 新的黄病毒抗原
JP2023533228A (ja) 安定化コロナウイルススパイク（ｓ）タンパク質免疫原および関連ワクチン
JP2003524392A (ja) 遺伝的ワクチンおよび酵素の非確率論的生成
US9284356B2 (en) Identification of a west nile virus CD4 T cell epitope and use thereof
EP3468590B1 (fr) Acides nucléiques codant pour des particules du type du virus zika et leur utilisation dans des vaccins contre le virus zika et des dosages de diagnostic
AU2018365296B2 (en) A Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
Sangewar et al. Novel potent IFN-γ–inducing CD8+ T cell epitopes conserved among diverse bovine viral diarrhea virus strains
Dupuy et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine
WO2018237313A1 (fr) Pseudo-particules virales comprenant un antigène zika
US20230034467A1 (en) Engineered HCV E2 Immunogens and Related Vaccine Compositions
KR20240122578A (ko) 조립된 당단백질
EP1555316A2 (fr) Immunisation par bibliothèque d'antigènes
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
CN102905725B (zh) 用于经典猪瘟的标记疫苗
Anticoli et al. Engineered exosomes boost the HCV NS3-specific CD8+ T lymphocyte immunity in humans
US20260041750A1 (en) Vaccine constructs comprising tuberculosis antigens
AU2761502A (en) Antigen library immunization
AU2017350853B2 (en) Mosaic vaccines for serotype a foot-and-mouth disease virus
Olszewska et al. Nasal delivery of epitope based vaccines
MXPA00007892A (en) Antigen library immunization
CN115867312B (zh) 产生引发针对病毒的非病毒粒子组成衍生表位的人白细胞抗原i类限制性cd8 t细胞应答的疫苗组合物的方法
BR112021001195A2 (pt) vacina, composição farmacêutica, peptídeo imunogênico isolado, composição, métodos para elicitar uma resposta imune em um sujeito, para produzir um anticorpo antiproteína ns1 de zika, para detectar uma infecção por zica vírus e para detectar células t específicas de zika vírus, e, uso de uma vacina, uma composição farmacêutica, um peptídeo imunogênico isolado ou uma composição.
US6534067B1 (en) Rotavirus enterotoxin adjuvant

Legal Events

Date Code Title Description
FZDE Discontinued